Disease · MONDO_0100342
Trials318
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.
1 to 20 of 318
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00602667 | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Phase 2 | 293 | 2019-01-30 | Brain and Central Nervous System Tumors | CYCLOPHOSPHAMIDE, METHOTREXATE, TOPOTECAN, VINBLASTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Phase 2 | 206 | 2023-08-21 | Cancer | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02655601 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 | Phase 1/2 | 177 | 2025-06-08 | High Grade Glioma, Astrocytoma, Grade III, Glioblastoma | BMX-001, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | Phase 2 | 166 | 2021-04-01 | Various Advanced Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | Phase 2 | 151 | 2014-01-24 | Glioma | AFATINIB, TEMOZOLOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01137604 | A Study in Subjects With Recurrent Malignant Glioma | Phase 2 | 151 | 2016-05-23 | Glioma | BEVACIZUMAB, LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | Phase 2 | 151 | 2023-05-19 | Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00892177 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | Phase 2 | 144 | 2017-06-27 | Glioblastoma Multiforme | BEVACIZUMAB, DASATINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | Phase 1/2 | 136 | 2017-07-13 | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Recurrent Adult Brain Tumor | ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | Phase 2 | 127 | 2018-03-07 | Glioblastoma, Gliomas | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04447755 | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) | Phase 2 | 127 | 2023-10-04 | Relapsed or Refractory Solid Tumors | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01390948 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | Phase 2 | 124 | 2017-08-04 | High Grade Glioma | BEVACIZUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02330562 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | Phase 1/2 | 121 | 2022-06-08 | Malignant Glioma, Glioblastoma | BEVACIZUMAB, MARIZOMIB | Its record names the disease | ClinicalTrials.gov |
| NCT02986178 | Lerapolturev in Recurrent Malignant Glioma | Phase 2 | 121 | 2025-07-11 | Malignant Glioma | LOMUSTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00953121 | Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) | Phase 2 | 104 | 2013-09-04 | Malignant Glioma | BEVACIZUMAB, CARBOPLATIN, IRINOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | Phase 2/3 | 101 | 2020-06-22 | Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Spinal Cord Neoplasm | BEVACIZUMAB, TEMOZOLOMIDE, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | Phase 2 | 97 | 2013-01-15 | Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma | BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | Phase 1/2 | 96 | 2016-09-23 | Malignant Glioma, Recurrent Glioblastoma | BEVACIZUMAB, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | Phase 2 | 87 | 2013-06-25 | Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas | SUNITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | Phase 1/2 | 86 | 2022-02-01 | Brain Tumor, Glioblastoma, Anaplastic Glioma | EVEROLIMUS, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100342/trials